Ocular Therapeutix Stock Price, News & Analysis (NASDAQ:OCUL)

$4.91 -0.04 (-0.81 %)
(As of 02/19/2018 04:00 PM ET)
Previous Close$4.91
Today's Range$4.87 - $5.08
52-Week Range$3.30 - $11.79
Volume304,492 shs
Average Volume590,676 shs
Market Capitalization$177.54 million
P/E Ratio-2.16
Dividend YieldN/A
Beta1.53

About Ocular Therapeutix (NASDAQ:OCUL)

Ocular Therapeutix logoOcular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.

Receive OCUL News and Ratings via Email

Sign-up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Equipment, Supplies & Distribution
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:OCUL
CUSIPN/A
Phone+1-781-8953235

Debt

Debt-to-Equity Ratio0.39%
Current Ratio4.79%
Quick Ratio4.78%

Price-To-Earnings

Trailing P/E Ratio-2.16299559471366
Forward P/E Ratio-2.13
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.89 million
Price / Sales96.46
Cash FlowN/A
Price / CashN/A
Book Value$2.06 per share
Price / Book2.38

Profitability

Trailing EPS($2.27)
Net Income$-44,700,000.00
Net Margins-3,241.19%
Return on Equity-126.31%
Return on Assets-81.51%

Miscellaneous

Employees118
Outstanding Shares37,130,000

Ocular Therapeutix (NASDAQ:OCUL) Frequently Asked Questions

What is Ocular Therapeutix's stock symbol?

Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."

How were Ocular Therapeutix's earnings last quarter?

Ocular Therapeutix Inc (NASDAQ:OCUL) issued its quarterly earnings data on Tuesday, November, 7th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.54). The biopharmaceutical company earned $523 million during the quarter, compared to the consensus estimate of $0.52 million. Ocular Therapeutix had a negative net margin of 3,241.19% and a negative return on equity of 126.31%. The company's revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.39) EPS. View Ocular Therapeutix's Earnings History.

When will Ocular Therapeutix make its next earnings announcement?

Ocular Therapeutix is scheduled to release their next quarterly earnings announcement on Wednesday, February, 28th 2018. View Earnings Estimates for Ocular Therapeutix.

Where is Ocular Therapeutix's stock going? Where will Ocular Therapeutix's stock price be in 2018?

6 Wall Street analysts have issued 12-month price targets for Ocular Therapeutix's stock. Their predictions range from $8.00 to $60.00. On average, they expect Ocular Therapeutix's stock price to reach $20.67 in the next twelve months. View Analyst Ratings for Ocular Therapeutix.

What are Wall Street analysts saying about Ocular Therapeutix stock?

Here are some recent quotes from research analysts about Ocular Therapeutix stock:

  • 1. According to Zacks Investment Research, "Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts. " (11/11/2017)
  • 2. Cantor Fitzgerald analysts commented, "Presentation at our conference emphasized added biopharma leadership experience to a previously medical technology-focused company." (9/25/2017)

Who are some of Ocular Therapeutix's key competitors?

Who are Ocular Therapeutix's key executives?

Ocular Therapeutix's management team includes the folowing people:

  • Amarpreet Sawhney Ph.D., Executive Chairman of the Board (Age 50)
  • Antony Charles Mattessich, President, Chief Executive Officer (Age 50)
  • Donald D. Notman Jr., Chief Financial Officer
  • Daniel M. Bollag Ph.D., Senior Vice President - Regulatory Affairs, Pharmacovigilance and Quality (Age 56)
  • Kevin Hanley, Senior Vice President - Technical Operations
  • Naymisha Patel, Vice President - Quality
  • Michael H. Goldstein M.D., Chief Medical Officer (Age 50)
  • Jaswinder S. Chadha, Director (Age 49)
  • W. James O'Shea, Director (Age 67)
  • Jeffrey S. Heier M.D., Independent Director (Age 56)

Who owns Ocular Therapeutix stock?

Ocular Therapeutix's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (6.78%), BlackRock Inc. (3.92%), Deltec Asset Management LLC (0.59%), Geode Capital Management LLC (0.47%), Hikari Power Ltd (0.27%) and Bank of New York Mellon Corp (0.19%). Company insiders that own Ocular Therapeutix stock include Amarpreet Sawhney, Antony C Mattessich, Daniel M Bollag and Donald Notman. View Institutional Ownership Trends for Ocular Therapeutix.

Who sold Ocular Therapeutix stock? Who is selling Ocular Therapeutix stock?

Ocular Therapeutix's stock was sold by a variety of institutional investors in the last quarter, including Deltec Asset Management LLC, Bank of Montreal Can, Bank of New York Mellon Corp and Geode Capital Management LLC. View Insider Buying and Selling for Ocular Therapeutix.

Who bought Ocular Therapeutix stock? Who is buying Ocular Therapeutix stock?

Ocular Therapeutix's stock was purchased by a variety of institutional investors in the last quarter, including Hikari Power Ltd, Virtu Financial LLC, Deutsche Bank AG, Jennison Associates LLC and BlackRock Inc.. Company insiders that have bought Ocular Therapeutix stock in the last two years include Amarpreet Sawhney, Antony C Mattessich, Daniel M Bollag and Donald Notman. View Insider Buying and Selling for Ocular Therapeutix.

How do I buy Ocular Therapeutix stock?

Shares of Ocular Therapeutix can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ocular Therapeutix's stock price today?

One share of Ocular Therapeutix stock can currently be purchased for approximately $4.91.

How big of a company is Ocular Therapeutix?

Ocular Therapeutix has a market capitalization of $177.54 million and generates $1.89 million in revenue each year. The biopharmaceutical company earns $-44,700,000.00 in net income (profit) each year or ($2.27) on an earnings per share basis. Ocular Therapeutix employs 118 workers across the globe.

How can I contact Ocular Therapeutix?

Ocular Therapeutix's mailing address is 15 Crosby Dr, BEDFORD, MA 01730-1401, United States. The biopharmaceutical company can be reached via phone at +1-781-8953235 or via email at [email protected]


MarketBeat Community Rating for Ocular Therapeutix (OCUL)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  188 (Vote Outperform)
Underperform Votes:  104 (Vote Underperform)
Total Votes:  292
MarketBeat's community ratings are surveys of what our community members think about Ocular Therapeutix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ocular Therapeutix (NASDAQ:OCUL) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.832.672.67
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $20.67$20.67$20.67$24.00
Price Target Upside: 273.04% upside273.04% upside295.91% upside315.22% upside

Ocular Therapeutix (NASDAQ:OCUL) Consensus Price Target History

Price Target History for Ocular Therapeutix (NASDAQ:OCUL)

Ocular Therapeutix (NASDAQ:OCUL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/19/2018BTIG ResearchUpgradeNeutral -> BuyHighView Rating Details
11/8/2017HC WainwrightReiterated RatingBuy$10.00N/AView Rating Details
10/23/2017GuggenheimInitiated CoverageBuy$12.00N/AView Rating Details
9/25/2017Cantor FitzgeraldReiterated RatingBuy$21.00LowView Rating Details
7/14/2017Morgan StanleyReiterated RatingEqual Weight$16.00 -> $8.00LowView Rating Details
3/13/2017CowenReiterated RatingOutperform$60.00MediumView Rating Details
11/15/2016Royal Bank of CanadaReiterated RatingOutperform$30.00 -> $32.00N/AView Rating Details
8/11/2016JMP SecuritiesInitiated CoverageOutperform$21.00 -> $5.84N/AView Rating Details
(Data available from 2/19/2016 forward)

Earnings

Ocular Therapeutix (NASDAQ:OCUL) Earnings History and Estimates Chart

Earnings by Quarter for Ocular Therapeutix (NASDAQ:OCUL)

Ocular Therapeutix (NASDAQ OCUL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2018($0.56)N/AView Earnings Details
11/7/2017Q3 2017($0.54)($0.54)$0.52 million$523.00 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.59)($0.64)$0.51 million$0.40 millionViewListenView Earnings Details
5/5/2017Q1 2017($0.48)($0.58)$0.51 million$0.48 millionViewN/AView Earnings Details
3/10/2017Q4 2016($0.45)($0.52)$0.48 million$0.51 millionViewN/AView Earnings Details
11/9/2016Q316($0.50)($0.39)$0.47 million$0.48 millionViewListenView Earnings Details
8/9/2016Q216($0.49)($0.46)$0.55 million$0.44 millionViewListenView Earnings Details
5/10/2016Q116($0.43)($0.44)$458.00 millionViewListenView Earnings Details
3/10/2016Q415($0.47)($0.43)$0.44 millionViewListenView Earnings Details
11/10/2015Q315($0.38)($0.47)$0.43 millionViewListenView Earnings Details
8/10/2015Q215($0.33)($0.45)$0.46 millionViewListenView Earnings Details
5/15/2015Q115($0.39)($0.35)$0.30 million$0.43 millionViewListenView Earnings Details
3/10/2015Q4($0.38)($0.37)$0.20 million$0.51 millionViewListenView Earnings Details
11/12/2014Q3 14($0.55)($0.48)$0.10 million$0.14 millionViewListenView Earnings Details
8/28/2014Q2 2014($2.31)($2.10)$0.10 million$0.10 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Ocular Therapeutix (NASDAQ:OCUL) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.31 EPS
Next Year EPS Consensus Estimate: $-2.22 EPS

Dividends

Dividend History for Ocular Therapeutix (NASDAQ:OCUL)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Ocular Therapeutix (NASDAQ OCUL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 26.10%
Institutional Ownership Percentage: 37.08%
Insider Trades by Quarter for Ocular Therapeutix (NASDAQ:OCUL)
Institutional Ownership by Quarter for Ocular Therapeutix (NASDAQ:OCUL)

Ocular Therapeutix (NASDAQ OCUL) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/12/2017Antony C MattessichInsiderBuy21,000$4.29$90,090.0021,000View SEC Filing  
12/7/2017Donald NotmanCFOBuy4,800$4.00$19,200.004,800View SEC Filing  
12/6/2017Daniel M BollagInsiderBuy24,700$3.93$97,071.0024,700View SEC Filing  
11/16/2017Amarpreet SawhneyChairmanBuy19,000$5.18$98,420.00696,390View SEC Filing  
12/15/2016Amarpreet SawhneyInsiderBuy45,300$7.85$355,605.00677,390View SEC Filing  
6/9/2016Amarpreet SawhneyCEOBuy10,000$6.70$67,000.00573,733View SEC Filing  
11/17/2015Amarpreet SawhneyCEOBuy10,000$8.25$82,500.00563,733View SEC Filing  
9/15/2015James FortuneCOOSell9,470$17.16$162,505.20112,060View SEC Filing  
9/14/2015Amarpreet SawhneyCEOBuy15,000$16.50$247,500.00553,733View SEC Filing  
6/15/2015Charles M WardenDirectorSell320,000$22.00$7,040,000.00View SEC Filing  
6/10/2015Charles M WardenDirectorSell427,000$22.00$9,394,000.00View SEC Filing  
6/10/2015Svlsf Iv, LlcMajor ShareholderSell1,119,000$22.00$24,618,000.00View SEC Filing  
7/30/2014Amarpreet SawhneyCEOBuy76,922$13.00$999,986.00View SEC Filing  
7/30/2014Svlsf Iv, LlcMajor ShareholderBuy715,380$13.00$9,299,940.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ocular Therapeutix (NASDAQ OCUL) News Headlines

Source:
DateHeadline
BRIEF-Summer Road Reports 8.4 Pct Passive Stake In Ocular TherapeutixBRIEF-Summer Road Reports 8.4 Pct Passive Stake In Ocular Therapeutix
www.reuters.com - February 8 at 3:42 PM
Ocular Therapeutix™ to Participate in the 2018 Glaucoma 360 Meeting in San FranciscoOcular Therapeutix™ to Participate in the 2018 Glaucoma 360 Meeting in San Francisco
finance.yahoo.com - February 8 at 8:11 AM
Ocular Therapeutix (OCUL) Downgraded by ValuEngineOcular Therapeutix (OCUL) Downgraded by ValuEngine
www.americanbankingnews.com - February 4 at 7:12 PM
Form 4 OCULAR THERAPEUTIX, INC For: Jan 31 Filed by: Mattessich Antony C. - StreetInsider.comForm 4 OCULAR THERAPEUTIX, INC For: Jan 31 Filed by: Mattessich Antony C. - StreetInsider.com
www.streetinsider.com - February 3 at 9:31 AM
Reviewing Haemonetics (HAE) & Ocular Therapeutix (OCUL)Reviewing Haemonetics (HAE) & Ocular Therapeutix (OCUL)
www.americanbankingnews.com - January 30 at 9:10 PM
Ocular TherapeutixTM Announces Closing of Public Offering of Common StockOcular TherapeutixTM Announces Closing of Public Offering of Common Stock
finance.yahoo.com - January 30 at 9:30 AM
Ocular Therapeutix Inc (OCUL) Receives Average Rating of "Buy" from BrokeragesOcular Therapeutix Inc (OCUL) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - January 30 at 3:28 AM
Pre-Open Movers 01/25: (DLB) (VAR) (MKC) Higher; (CFMS) (OCUL) (NWL) Lower (more...)Pre-Open Movers 01/25: (DLB) (VAR) (MKC) Higher; (CFMS) (OCUL) (NWL) Lower (more...)
www.streetinsider.com - January 25 at 3:44 PM
Ocular Therapeutix™ Announces Proposed Public Offering of Common StockOcular Therapeutix™ Announces Proposed Public Offering of Common Stock
finance.yahoo.com - January 25 at 9:37 AM
Ocular TherapeutixTM Announces Pricing of Public Offering of Common StockOcular TherapeutixTM Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - January 25 at 9:37 AM
Ocular Therapeutix (OCUL) Upgraded at BTIG ResearchOcular Therapeutix (OCUL) Upgraded at BTIG Research
www.americanbankingnews.com - January 20 at 7:38 PM
Lombard Medical (EVARF) vs. Ocular Therapeutix (OCUL) Head-To-Head SurveyLombard Medical (EVARF) vs. Ocular Therapeutix (OCUL) Head-To-Head Survey
www.americanbankingnews.com - January 18 at 11:18 AM
Head to Head Survey: Ocular Therapeutix (OCUL) & Alliqua Biomedical (ALQA)Head to Head Survey: Ocular Therapeutix (OCUL) & Alliqua Biomedical (ALQA)
www.americanbankingnews.com - January 9 at 5:10 AM
Ocular Therapeutix™ Announces Kevin Hanley as Senior Vice President, Technical Operations and Naymisha Patel as Vice President of QualityOcular Therapeutix™ Announces Kevin Hanley as Senior Vice President, Technical Operations and Naymisha Patel as Vice President of Quality
finance.yahoo.com - January 8 at 10:31 AM
Ocular Therapeutix Inc (OCUL) Given Consensus Rating of "Hold" by AnalystsOcular Therapeutix Inc (OCUL) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - January 5 at 3:38 AM
Ocular Therapeutix, Inc. :OCUL-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018Ocular Therapeutix, Inc. :OCUL-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018
finance.yahoo.com - January 1 at 10:11 AM
ETFs with exposure to Ocular Therapeutix, Inc. : December 26, 2017ETFs with exposure to Ocular Therapeutix, Inc. : December 26, 2017
finance.yahoo.com - December 26 at 4:18 PM
Ocular Therapeutix (OCUL) Provides Legal Update on Matters Related to DEXTENZA - StreetInsider.comOcular Therapeutix (OCUL) Provides Legal Update on Matters Related to DEXTENZA - StreetInsider.com
www.streetinsider.com - December 23 at 4:20 AM
Ocular Therapeutix™ Provides Legal UpdateOcular Therapeutix™ Provides Legal Update
finance.yahoo.com - December 22 at 7:31 PM
Ocular Therapeutix gets subpoena from SEC over eye pain drugOcular Therapeutix gets subpoena from SEC over eye pain drug
finance.yahoo.com - December 22 at 7:31 PM
Insider Buying: Ocular Therapeutix, Inc. (OCUL) Insider Purchases 21,000 Shares of StockInsider Buying: Ocular Therapeutix, Inc. (OCUL) Insider Purchases 21,000 Shares of Stock
www.americanbankingnews.com - December 13 at 9:50 PM
Ocular Therapeutix, Inc. (OCUL) Given Consensus Rating of "Hold" by BrokeragesOcular Therapeutix, Inc. (OCUL) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - December 11 at 3:38 AM
Ocular Therapeutix, Inc. (OCUL) CFO Donald Notman Purchases 4,800 SharesOcular Therapeutix, Inc. (OCUL) CFO Donald Notman Purchases 4,800 Shares
www.americanbankingnews.com - December 8 at 6:46 PM
Daniel M. Bollag Buys 24,700 Shares of Ocular Therapeutix, Inc. (OCUL) StockDaniel M. Bollag Buys 24,700 Shares of Ocular Therapeutix, Inc. (OCUL) Stock
www.americanbankingnews.com - December 8 at 6:20 PM
Financial Contrast: Ocular Therapeutix (OCUL) vs. Capnia (SLNO)Financial Contrast: Ocular Therapeutix (OCUL) vs. Capnia (SLNO)
www.americanbankingnews.com - December 8 at 5:14 PM
Ocular Therapeutix™ to Participate in the Guggenheim Securities 5 - Business Wire (press release)Ocular Therapeutix™ to Participate in the Guggenheim Securities 5 - Business Wire (press release)
www.businesswire.com - December 6 at 10:36 AM
Was Ocular Therapeutix Inc’s (OCUL) EPS Decline A Part Of Broader Industry Downturn?Was Ocular Therapeutix Inc’s (OCUL) EPS Decline A Part Of Broader Industry Downturn?
finance.yahoo.com - December 4 at 4:35 PM
Analyzing Ocular Therapeutix (OCUL) and C.R. Bard (BCR)Analyzing Ocular Therapeutix (OCUL) and C.R. Bard (BCR)
www.americanbankingnews.com - November 27 at 7:08 PM
Insider Buying: Ocular Therapeutix, Inc. (OCUL) Chairman Acquires 19,000 Shares of StockInsider Buying: Ocular Therapeutix, Inc. (OCUL) Chairman Acquires 19,000 Shares of Stock
www.americanbankingnews.com - November 20 at 10:50 AM
Ocular Therapeutix, Inc. (OCUL) Given Consensus Recommendation of "Hold" by AnalystsOcular Therapeutix, Inc. (OCUL) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 16 at 3:38 AM
Ocular Therapeutix, Inc. (OCUL) Upgraded to "Hold" at Zacks Investment ResearchOcular Therapeutix, Inc. (OCUL) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - November 11 at 7:16 AM
Edited Transcript of OCUL earnings conference call or presentation 7-Nov-17 10:00pm GMTEdited Transcript of OCUL earnings conference call or presentation 7-Nov-17 10:00pm GMT
finance.yahoo.com - November 9 at 8:00 AM
Ocular Therapeutix, Inc. (OCUL) Given Buy Rating at HC WainwrightOcular Therapeutix, Inc. (OCUL) Given Buy Rating at HC Wainwright
www.americanbankingnews.com - November 8 at 10:26 PM
Critical Contrast: Ocular Therapeutix (OCUL) & Its PeersCritical Contrast: Ocular Therapeutix (OCUL) & Its Peers
www.americanbankingnews.com - November 8 at 2:08 PM
Ocular Therapeutix, Inc. (OCUL) Issues Quarterly  Earnings ResultsOcular Therapeutix, Inc. (OCUL) Issues Quarterly Earnings Results
www.americanbankingnews.com - November 7 at 5:27 PM
Ocular Therapeutix Inc to Host Earnings CallOcular Therapeutix Inc to Host Earnings Call
finance.yahoo.com - November 7 at 4:40 PM
Ocular Therapeutix™ Reports Third Quarter 2017 Financial Results and Provides Corporate UpdateOcular Therapeutix™ Reports Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - November 7 at 4:40 PM
Ocular Therapeutix (OCUL) vs. MiMedx Group (MDXG) Critical ContrastOcular Therapeutix (OCUL) vs. MiMedx Group (MDXG) Critical Contrast
www.americanbankingnews.com - November 7 at 2:06 PM
Head-To-Head Comparison: Ocular Therapeutix (OCUL) & Its PeersHead-To-Head Comparison: Ocular Therapeutix (OCUL) & Its Peers
www.americanbankingnews.com - November 4 at 10:12 AM
Ocular Therapeutix™ to Report Third Quarter 2017 Financial ResultsOcular Therapeutix™ to Report Third Quarter 2017 Financial Results
finance.yahoo.com - November 1 at 7:12 AM
Ocular Therapeutix, Inc. (OCUL) Scheduled to Post Quarterly Earnings on TuesdayOcular Therapeutix, Inc. (OCUL) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 9:26 AM
Financial Review: Integra LifeSciences Holdings Corporation (IART) vs. Ocular Therapeutix (OCUL)Financial Review: Integra LifeSciences Holdings Corporation (IART) vs. Ocular Therapeutix (OCUL)
www.americanbankingnews.com - October 26 at 11:36 AM
Ocular Therapeutix (OCUL) versus Its Peers Head to Head ComparisonOcular Therapeutix (OCUL) versus Its Peers Head to Head Comparison
www.americanbankingnews.com - October 23 at 6:28 PM
Ocular Therapeutix, Inc. (OCUL) Coverage Initiated by Analysts at GuggenheimOcular Therapeutix, Inc. (OCUL) Coverage Initiated by Analysts at Guggenheim
www.americanbankingnews.com - October 23 at 6:20 PM
Ocular Therapeutix, Inc. (OCUL) Receives Consensus Recommendation of "Hold" from AnalystsOcular Therapeutix, Inc. (OCUL) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 22 at 4:42 AM
Ocular Therapeutix Is Now Oversold (OCUL)Ocular Therapeutix Is Now Oversold (OCUL)
www.thestreet.com - October 20 at 7:05 AM
Ocular Therapeutix™ Appoints Donald Notman as Chief Financial OfficerOcular Therapeutix™ Appoints Donald Notman as Chief Financial Officer
finance.yahoo.com - October 2 at 7:52 PM
Robbins Arroyo LLP Is Investigating the Officers and Directors of Ocular Therapeutix, Inc. (OCUL) on Behalf of ShareholdersRobbins Arroyo LLP Is Investigating the Officers and Directors of Ocular Therapeutix, Inc. (OCUL) on Behalf of Shareholders
finance.yahoo.com - October 2 at 7:52 PM
How Does Investing In Ocular Therapeutix Inc (OCUL) Impact Your Portfolio?How Does Investing In Ocular Therapeutix Inc (OCUL) Impact Your Portfolio?
finance.yahoo.com - October 2 at 7:52 PM
Financial Review: NuVasive (NUVA) vs. Ocular Therapeutix (OCUL)Financial Review: NuVasive (NUVA) vs. Ocular Therapeutix (OCUL)
www.americanbankingnews.com - October 1 at 8:24 AM

SEC Filings

Ocular Therapeutix (NASDAQ:OCUL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ocular Therapeutix (NASDAQ:OCUL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ocular Therapeutix (NASDAQ OCUL) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.